Drug Trial Radar · NCT05759897
A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Mar 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
180
Planned (sponsor's estimate)
Start
Feb 28, 2023
Primary completion
Dec 21, 2023
Study completion Jan 4, 2024
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with type 2 diabetes mellitus.
Conditions
- Type 2 Diabetes
Interventions
HRS-7535Drug
HRS-7535
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in HbA1c at Week 16Time frame: at Week 16]
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.